Previous 10 | Next 10 |
OSAKA, Japan , and KING OF PRUSSIA, Pa. , May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building...
The FDA designates Takeda Pharmaceutical Company Limited's (NYSE: TAK ) mobocertinib (TAK-788) a Breakthrough Therapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has ...
Avadel Pharmaceuticals (NASDAQ: AVDL ) jumps 30% premarket on average volume in reaction to positive results from a Phase 3 clinical trial, REST-ON , evaluating lead candidate FT218, a once-nightly formulation of sodium oxybate, for the treatment of excessive daytime sleepines...
– Designation Represents Positive Progress for a Unique Patient Population in Need of Targeted Therapy Options Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakth...
Takeda Teams Up with ProThera on IAIP Therapy Takeda Pharmaceutical Company Limited ( TAK ) announced inking a new deal with ProThera Biologics for the purpose of developing IAIP therapy. This plasma-derived therapy is intended to be used for treating acute inflammatory conditions. Both th...
Portfolio includes select OTC and prescription products and two manufacturing facilities Transaction further accelerates Company’s deleveraging plan Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has entered into...
Takeda Pharmaceutical Company Limited ( TAK +1.3% ) inks an agreement with ProThera Biologics aimed at developing the latter's plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for acute inflammatory conditions. More news on: Takeda Pharmaceutical Company Limited, Health...
PROVIDENCE, R.I. , and OSAKA, Japan , April 23, 2020 /PRNewswire/ -- ProThera Biologics, Inc . and Takeda Pharmaceutical Company Limited [ TSE:4502/NYSE:TAK ] ("Takeda") today announced that they have entered into a global licensing agreement to develop a novel plasma-derived...
As the medical community explores plasma therapy to treat severe COVID-19 patients, Microsoft (NASDAQ: MSFT ) is launching an initiative this weekend to encourage people who have recovered from the disease to donate their plasma. More news on: Microsoft Corporation, Takeda Pharmaceutical...
When Takeda Pharmaceutical ( TAK ) said that it would develop a coronavirus vaccine, the stock briefly rose. But the real driver for the company's growth will not come from this market. Currently, the main players in the coronavirus treatment will earn almost nothing. Gilead Sciences (...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...